| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship.
|
Cancer Res
|
2004
|
2.41
|
|
2
|
Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients.
|
Blood
|
2012
|
1.89
|
|
3
|
Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20.
|
Blood
|
2008
|
1.56
|
|
4
|
Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study.
|
J Clin Oncol
|
2013
|
1.22
|
|
5
|
Obinutuzumab (GA101) in patients with relapsed/refractory indolent non-Hodgkin lymphoma: results from the phase II GAUGUIN study.
|
J Clin Oncol
|
2013
|
1.20
|
|
6
|
Evidence for linkage disequilibrium between Fcgamma RIIIa-V158F and Fcgamma RIIa-H131R polymorphisms in white patients, and for an Fcgamma RIIIa-restricted influence on the response to therapeutic antibodies.
|
J Clin Oncol
|
2008
|
1.12
|
|
7
|
Clinical radioimmunotherapy--the role of radiobiology.
|
Nat Rev Clin Oncol
|
2011
|
1.10
|
|
8
|
Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study.
|
Blood
|
2012
|
1.09
|
|
9
|
Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial.
|
J Clin Oncol
|
2012
|
1.03
|
|
10
|
Relevance, advantages and limitations of animal models used in the development of monoclonal antibodies for cancer treatment.
|
Crit Rev Oncol Hematol
|
2007
|
1.00
|
|
11
|
Impact of the use of autologous stem cell transplantation at first relapse both in naive and previously rituximab exposed follicular lymphoma patients treated in the GELA/GOELAMS FL2000 study.
|
Haematologica
|
2011
|
1.00
|
|
12
|
CXCL12 polymorphism and malignant cell dissemination/tissue infiltration in acute myeloid leukemia.
|
FASEB J
|
2006
|
1.00
|
|
13
|
Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000).
|
Blood
|
2013
|
0.93
|
|
14
|
Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms.
|
Blood
|
2012
|
0.91
|
|
15
|
Rituximab induces different but overlapping sets of genes in human B-lymphoma cell lines.
|
Cancer Immunol Immunother
|
2004
|
0.85
|
|
16
|
Citrobacter koseri cellulitis during anti-CD20 monoclonal antibody (ofatumumab) treatment for B-cell chronic lymphocytic leukaemia.
|
Acta Derm Venereol
|
2010
|
0.85
|
|
17
|
Obinutuzumab: a new class of anti-CD20 monoclonal antibody.
|
Curr Opin Oncol
|
2014
|
0.84
|
|
18
|
Development of a drug-disease simulation model for rituximab in follicular non-Hodgkin's lymphoma.
|
Br J Clin Pharmacol
|
2009
|
0.84
|
|
19
|
Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma.
|
Haematologica
|
2013
|
0.84
|
|
20
|
Autologous stem cell transplantation in mantle cell lymphoma: a report from the SFGM-TC.
|
Ann Hematol
|
2013
|
0.84
|
|
21
|
Localized low-dose radiotherapy for follicular lymphoma: history, clinical results, mechanisms of action, and future outlooks.
|
Int J Radiat Oncol Biol Phys
|
2010
|
0.83
|
|
22
|
Comparison of EBV DNA viral load in whole blood, plasma, B-cells and B-cell culture supernatant.
|
J Med Virol
|
2013
|
0.81
|
|
23
|
Residual malignant and normal plasma cells shortly after high dose melphalan and stem cell transplantation. Highlight of a putative therapeutic window in Multiple Myeloma?
|
Oncotarget
|
2012
|
0.80
|
|
24
|
Model-based design of rituximab dosage optimization in follicular non-Hodgkin's lymphoma.
|
Br J Clin Pharmacol
|
2012
|
0.79
|
|
25
|
Online high-efficiency haemodiafiltration achieves higher serum free light chain removal than high-flux haemodialysis in multiple myeloma patients: preliminary quantitative study.
|
Nephrol Dial Transplant
|
2011
|
0.79
|
|
26
|
Increased T-cell activation and Th1 cytokine concentrations prior to the diagnosis of B-cell lymphoma in HIV infected patients.
|
J Clin Immunol
|
2012
|
0.79
|
|
27
|
Frequency and differentiation capacity of circulating LTC-IC mobilized by G-CSF or GM-CSF following chemotherapy: a comparison with steady-state bone marrow and peripheral blood.
|
Exp Hematol
|
2002
|
0.78
|
|
28
|
Long-term marrow reconstitutive ability of autologous grafts in lymphoma patients using peripheral blood mobilized with granulocyte colony-stimulating factor or granulocyte-macrophage colony-stimulating factor compared to bone marrow.
|
Exp Hematol
|
2003
|
0.78
|
|
29
|
Long-term outcome of localized high-grade non-Hodgkin's lymphoma treated with high dose CHOP regimen and involved field radiotherapy: results of a GOELAMS study.
|
Haematologica
|
2005
|
0.77
|
|
30
|
High ratio of interfollicular CD8/FOXP3-positive regulatory T cells is associated with a high FLIPI index and poor overall survival in follicular lymphoma.
|
Exp Ther Med
|
2010
|
0.76
|
|
31
|
DNA repair in diffuse large B-cell lymphoma: a molecular portrait.
|
Br J Haematol
|
2014
|
0.76
|
|
32
|
Dose-response relationship and pharmacogenetics of anti-RhD monoclonal antibodies.
|
Blood
|
2005
|
0.75
|
|
33
|
New anti-CD20 monoclonal antibodies: which is the best?
|
Leuk Lymphoma
|
2014
|
0.75
|
|
34
|
[Monoclonal antibody therapy for non-Hodgkin's lymphoma].
|
Rev Prat
|
2010
|
0.75
|
|
35
|
High response rate and acceptable toxicity of a combination of rituximab, vinorelbine, ifosfamide, mitoxantrone and prednisone for the treatment of diffuse large B-cell lymphoma in first relapse: results of the R-NIMP GOELAMS study.
|
Br J Haematol
|
2013
|
0.75
|
|
36
|
Autologous stem cell transplantation in mantle cell lymphoma: a report from the SFGM-TC.
|
Ann Hematol
|
2014
|
0.75
|